Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.
about
Cognitive enhancers for the treatment of ADHDNoradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilienceThe use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorderAlpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animalsMethylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.Animal models of attention-deficit hyperactivity disorder.Reducing substance use during adolescence: a translational framework for preventionTargeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive DisordersChanges in postnatal norepinephrine alter alpha-2 adrenergic receptor development.Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth.Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorderα2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapySpecificity of the effect of a nicotinic receptor polymorphism on individual differences in visuospatial attention.Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions.Pharmacological enhancement of memory and executive functioning in laboratory animals.HCN channels in behavior and neurological disease: too hyper or not active enough?Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for deliriumMolecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning.Beta2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals.Lack of kinase-independent activity of PI3Kγ in locus coeruleus induces ADHD symptoms through increased CREB signaling.Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonistsEffects of α-2A adrenergic receptor agonist on time and risk preference in primatesAdrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilinNoradrenergic dysfunction in Alzheimer's disease.Regulation of alpha2AR trafficking and signaling by interacting proteins.Psychopharmacological characterisation of the successive negative contrast effect in ratsGuanfacine for the treatment of cognitive disorders: a century of discoveries at YaleChanges in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes.Experimental strategies for investigating psychostimulant drug actions and prefrontal cortical function in ADHD and related attention disorders.Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder.Norepinephrine versus dopamine and their interaction in modulating synaptic function in the prefrontal cortex.Selective suppression of excitatory synapses on GABAergic interneurons by norepinephrine in juvenile rat prefrontal cortical microcircuitryPharmacological and therapeutic directions in ADHD: Specificity in the PFC.Impaired cognition and attention in adults: pharmacological management strategies.Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function.The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss.Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure.
P2860
Q22251235-0C076746-D1A7-475E-A729-97AC0A47D6D0Q22337457-80E1D4D5-3FB0-4026-AE71-A72528B71165Q24629736-D56B687B-77B0-4ECD-924E-47D20F5D0E16Q24682060-092A28B1-6624-45D7-9FF4-3C3661884402Q24810310-D9EC2934-640B-44E1-8ACD-CE2F258BA12CQ24814868-99B5E2B1-A63E-4310-BDCD-4A917D690861Q27023852-98E69E1E-8B9D-4815-B98E-051388B86AF8Q28076907-A8BFD9D6-0835-428E-8D66-40DC037EB966Q30463333-A1BF850D-9C36-47E8-9CD5-F4C7611C2BFBQ30467190-69E8BD01-2C37-43DD-B8A5-0E655C114856Q30480908-BEE97D16-CB4D-4A68-A267-4C22EFF49240Q33571104-5FDC3B67-5C63-49FB-96C9-DDC76F57989DQ34295208-D40493D6-7132-46C1-BCDB-20122F9092EEQ34312472-CF721898-DA3E-43B1-AAEF-F66F5F381E28Q34424490-6DA69872-0D00-433D-9801-B310946891DDQ34661221-96D1FBA2-2C1B-4CB0-9E51-015F17130F60Q34777401-1271CECC-1E13-4E1B-8584-EA9E6B114F32Q34784435-70A47BA9-CC35-493F-8387-6ACFB2E1E667Q35028276-FF1E68DF-C1AD-4C54-8F67-65F9494C9EA9Q35130800-DECA567F-1876-4BCB-86F5-6D73648AAAC6Q35157911-A940233C-5495-480C-99FE-55F5F430FD97Q35604751-431C4D00-3A53-4646-9C8E-8027EA60FBC8Q35644004-9FD5F2F3-B999-4D61-84CF-096D9833E7BDQ35721180-A9FF88B3-6C92-4173-A00C-C01D6CEDDE01Q35722397-4FB8AF5E-4967-4843-ABEB-61739020A986Q35749478-D862C206-B09D-4664-8E99-6A53B422FD69Q35828056-2598031C-CCB4-4A83-9D65-1030E67B38EBQ35851639-94867DED-B021-446C-BA88-054C4FC6BAE3Q35855475-2902E2B0-DECD-45B0-BC42-247D5232DCAFQ36103023-FBEE3E0D-8C02-4FEA-BA8A-BA43444F61F7Q36445410-BF802A61-CC28-4459-8F8A-EC611A75DB2EQ36446854-CEE40B4B-4F9A-441F-9355-6669C7F148B7Q36914029-5BC69F09-CBE4-48E2-B44C-0604668DD333Q36932540-BE4F7867-1172-41CC-9D06-A31E9E2C02E5Q36968713-6A1C1E50-25E5-47C5-AA38-B4AEF70ACFC6Q37096227-E0E8F4CE-4DD0-47DC-9CA4-29EB52098637Q37125488-6D165102-D388-466B-8A30-3D118D9BE96BQ37203807-ABBEC875-7CB3-444F-B132-1D9BB2F9285EQ37469310-B8020E87-99AD-4CF2-8842-5A778B54310FQ37529127-CAE77087-A6BA-43CB-8025-80A0E1E432F3
P2860
Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Mutation of the alpha2A-adreno ...... ive enhancement by guanfacine.
@en
Mutation of the alpha2A-adreno ...... ive enhancement by guanfacine.
@nl
type
label
Mutation of the alpha2A-adreno ...... ive enhancement by guanfacine.
@en
Mutation of the alpha2A-adreno ...... ive enhancement by guanfacine.
@nl
prefLabel
Mutation of the alpha2A-adreno ...... ive enhancement by guanfacine.
@en
Mutation of the alpha2A-adreno ...... ive enhancement by guanfacine.
@nl
P2093
P1476
Mutation of the alpha2A-adreno ...... tive enhancement by guanfacine
@en
P2093
Amy F T Arnsten
Brian K Kobilka
Catherine M Dailey Borja
Jenna S Franowicz
Lee E Limbird
Lynn E Kessler
P304
P356
10.1523/JNEUROSCI.22-19-08771.2002
P407
P577
2002-10-01T00:00:00Z